Bio-Rad Reliance RT-PCR COVID assays granted EUA
April 2021—Bio-Rad Laboratories announced that its Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR assay kits were granted emergency use authorization by the FDA.
Webinars and Sponsored Roundtables — Register Now
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
FDA authorizes QuickVue At-Home COVID-19 test
April 2021—The FDA issued an emergency use authorization for the Quidel QuickVue At-Home COVID-19 test.
QIAsphere cloud-based connectivity solution
April 2021—Qiagen launched its QIAsphere cloud-based platform, which will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.
Center for Phlebotomy Education training video
April 2021—The Center for Phlebotomy Education has released a training video from its Applied Phlebotomy series that can be streamed online through the Phlebotomy Channel.
Sarstedt specimen transport system
April 2021—Sarstedt introduced its dedicated transportation system for sending specimen tubes to the laboratory, the Tempus600. Sample tubes are placed directly into a sending station and arrive within seconds at a laboratory receiving station for processing. An optional connection module enables tubes to be loaded directly into laboratory automation systems, such as the Sarstedt BL 1200 bulk loader and sorter. The Tempus600 system and pipelines require little space, and installation takes two weeks.
FDA authorizes Cue Health’s OTC COVID-19 test
April 2021—Cue Health has received FDA emergency use authorization for over-the-counter sale of its COVID-19 test. The Cue COVID-19 Test for Home and Over the Counter Use uses a lower nasal swab and provides results in about 20 minutes. The Cue OTC test is authorized for use by symptomatic and asymptomatic individuals, ages two and older.
PerkinElmer assay gets EUA for asymptomatic testing
April 2021—PerkinElmer announced that its PerkinElmer New Coronavirus Nucleic Acid Detection Kit received emergency use authorization from the FDA to test individuals without symptoms or other reasons to suspect COVID-19 infection.
Quidel gets EUA for Solana SARS molecular test
March 2021—Quidel received emergency use authorization from the FDA to market its Solana SARS-CoV-2 assay, an isothermal reverse transcriptase–helicase dependent amplification (RT-HDA) assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal and nasal swab specimens in viral transport media from patients suspected of having COVID-19 by their health care provider.
Visby POC COVID-19 PCR test gets CLIA waiver
March 2021—Visby Medical announced FDA authorization of the company’s rapid PCR COVID-19 test for use at the point of care by organizations with a CLIA certificate of waiver.
Siemens lab-based COVID-19 antigen test
March 2021—Siemens Healthineers announced the company’s laboratory-based SARS-CoV-2 Antigen Assay obtained the CE mark. The test runs on the Atellica IM analyzer, which has the capacity to run 440 tests per hour, and the Advia Centaur XP and XPT immunoassay systems.